| |
NON-EAOC
|
EAOC
|
P
|
|---|
|
FIGO Stagea
| | |
<.0001*
|
|
I
|
92 (39.15%)
|
49 (71.01%)
| |
|
II
|
32 (13.62%)
|
12 (17.39%)
| |
|
III
|
97 (41.28%)
|
7 (10.14%)
| |
|
IV
|
14 (5.96%)
|
1 (1.45%)
| |
|
Early or late Stage
| | |
<.0001*
|
|
I + II
|
124 (52.77%)
|
61 (88.41%)
| |
|
III + IV
|
111 (47.23%)
|
8 (11.59%)
| |
|
Lymphadenectomy
| | |
0.0160*
|
|
Yes
|
189 (80.43%)
|
64 (92.75%)
| |
|
No
|
46 (19.57%)
|
5 (7.25%)
| |
|
Residual disease
| | |
0.0002*
|
|
No or <1 cm
|
167 (71.06%)
|
64 (92.75%)
| |
|
> 1 cm
|
68 (28.94%)
|
5 (7.25%)
| |
|
Metastasis of lymph node
| | |
0.0060*
|
|
Yes
|
35 (14.89%)
|
5 (7.25%)
| |
|
No
|
154 (65.53%)
|
59 (85.51%)
| |
|
Not-dissected
|
46 (19.57%)
|
5 (7.25%)
| |
|
Histotype
| | |
0.0041*
|
|
Clear cell
|
81 (34.47%)
|
37 (53.62%)
| |
|
Endometrioid
|
154 (65.53%)
|
32 (46.38%)
| |
|
Endometrial disorders
| | |
0.0808*
|
|
Yes
|
45 (19.15%)
|
7 (10.14%)
| |
|
No
|
190 (80.85%)
|
62 (89.86%)
| |
|
Endometrial cancer
| | |
0.051
|
|
Yes
|
25 (23.8%)
|
2 (7.4%)
| |
|
No
|
211 (76.2%)
|
66 (92.6%)
| |
|
Chemotherapy
| | |
0.6250
|
|
Platinum-based
|
224 (95.32%)
|
67 (97.1%)
| |
|
Other regimen
|
3 (1.28%)
|
0 (0%)
| |
|
No chemotherapy
|
8 (3.4%)
|
2 (2.9%)
| |
|
Chemo Cycles
|
6.36 ± 2.33
|
5.70 ± 2.05
|
0.039*
|
|
Chemo-resistance
| | |
0.0149*
|
|
Yes
|
47 (20%)
|
5 (7.35%)
| |
|
No
|
188 (80%)
|
63 (92.65%)
| |
- Abbreviation: EOC, epithelial ovarian carcinoma; FIGO, International Federation of Gynecology and Obstetrics; EM, endometriosis; EAOC, endometriosis-associated ovarian cancer
- *the difference reached statistical significance
-
aaccording to the classification system of FIGO staging (2013 version)
